Have a personal or library account? Click to login
Feasibility, Effectiveness, and Acceptability of a Telemedicine Neurological Consultation for Drug-Induced Movement Disorders; A Randomized Pilot Study Cover

Feasibility, Effectiveness, and Acceptability of a Telemedicine Neurological Consultation for Drug-Induced Movement Disorders; A Randomized Pilot Study

Tremor and Other Hyperkinetic Movements
Volume 15 (2025): Issue 1
By: Emily HoustonORCID,  Amanda G. KennedyORCID,  Terry Rabinowitz,  Gail L. RoseORCID and  James Boyd  
Open Access
|May 2025

References

  1. 1Factor SA, Burkhard PR, Caroff S, et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol. 2019;18:880–90. DOI: 10.1016/S1474-4422(19)30152-8
    Back to article
  2. 2Niemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018;78:525–41. DOI: 10.1007/s40265-018-0874-x
    Back to article
  3. 3Preskorn SH. The Evolution of Antipsychotic Drug Therapy: Reserpine, Chlorpromazine, and Haloperidol. Journal of Psychiatric Practice®. 2007;13:253–7. DOI: 10.1097/01.pra.0000281486.34817.8b
    Back to article
  4. 4Rifkin A. Extrapyramidal side effects: a historical perspective. J Clin Psychiatry. 1987;48 Suppl:3–6.
    Back to article
  5. 5Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry. 2022;13:1069432. DOI: 10.3389/fpsyt.2022.1069432
    Back to article
  6. 6Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017;18:1279–87. DOI: 10.1080/14656566.2017.1353078
    Back to article
  7. 7Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78:e264–e78. DOI: 10.4088/JCP.16r10832
    Back to article
  8. 8Mentzel TQ, Lieverse R, Bloemen O, et al. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. J Clin Psychopharmacol. 2017;37:231–8. DOI: 10.1097/JCP.0000000000000666
    Back to article
  9. 9Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27:208–17. DOI: 10.1017/S109285292000200X
    Back to article
  10. 10McEvoy JP, Kremens DE. Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia. J Clin Psychiatry. 2020;81. DOI: 10.4088/JCP.NU18041AH5C
    Back to article
  11. 11Bashir HH, Jankovic J. Treatment of Tardive Dyskinesia. Neurol Clin. 2020;38:379–96. DOI: 10.1016/j.ncl.2020.01.004
    Back to article
  12. 12McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28:3303–12. DOI: 10.1007/s11136-019-02269-8
    Back to article
  13. 13Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785–94. DOI: 10.2147/NDT.S196541
    Back to article
  14. 14Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117313. DOI: 10.1177/20451253221117313
    Back to article
  15. 15Ben-Pazi H, Browne P, Chan P, et al. The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. Curr Neurol Neurosci Rep. 2018;18:26. DOI: 10.1007/s11910-018-0834-6
    Back to article
  16. 16Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80:1989–96. DOI: 10.1212/WNL.0b013e318293e2ce
    Back to article
  17. 17El-Mallakh RS, Belnap A, Iyer S, et al. Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel. Telemed J E Health. 2023;29:1096–104. DOI: 10.1089/tmj.2022.0234
    Back to article
  18. 18Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: the example of Parkinson’s disease. Lancet Neurol. 2017;16:541–51. DOI: 10.1016/S1474-4422(17)30167-9
    Back to article
  19. 19Srinivasan R, Ben-Pazi H, Dekker M, et al. Telemedicine for Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2020;10. DOI: 10.5334/tohm.534
    Back to article
  20. 20Dorsey ER, Deuel LM, Voss TS, et al. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson’s disease. Mov Disord. 2010;25:1652–9. DOI: 10.1002/mds.23145
    Back to article
  21. 21Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5:233–7. DOI: 10.1016/0149-7189(82)90074-X
    Back to article
  22. 22Hammert WC, Calfee RP. Understanding PROMIS. J Hand Surg Am. 2020;45:650–4. DOI: 10.1016/j.jhsa.2020.03.016
    Back to article
  23. 23Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81. DOI: 10.1016/j.jbi.2008.08.010
    Back to article
  24. 24O’Reilly R, Bishop J, Maddox K, Hutchinson L, Fisman M, Takhar J. Is telepsychiatry equivalent to face-to-face psychiatry? Results from a randomized controlled equivalence trial. Psychiatr Serv. 2007;58:836–43. DOI: 10.1176/ps.2007.58.6.836
    Back to article
  25. 25Schubert NJ, Backman PJ, Bhatla R, Corace KM. Telepsychiatry and patient-provider concordance. Can J Rural Med. 2019;24:75–82. DOI: 10.4103/CJRM.CJRM_9_18
    Back to article
  26. 26Bishop JE, O’Reilly RL, Maddox K, Hutchinson LJ. Client satisfaction in a feasibility study comparing face-to-face interviews with telepsychiatry. J Telemed Telecare. 2002;8:217–21. DOI: 10.1258/135763302320272185
    Back to article
  27. 27Urness D, Wass M, Gordon A, Tian E, Bulger T. Client acceptability and quality of life—telepsychiatry compared to in-person consultation. J Telemed Telecare. 2006;12:251–4. DOI: 10.1258/135763306777889028
    Back to article
  28. 28Gallegos-Rejas VM, Thomas EE, Kelly JT, Smith AC. A multi-stakeholder approach is needed to reduce the digital divide and encourage equitable access to telehealth. J Telemed Telecare. 2023;29:73–8. DOI: 10.1177/1357633X221107995
    Back to article
  29. 29Interpret Scores- PROMIS®. 2024. (Accessed Sept 19, 2024, at https://www.healthmeasures.net/score-and-interpret/interpret-scores/promis.).
    Back to article
  30. 30Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92. DOI: 10.1097/01.MLR.0000062554.74615.4C
    Back to article
DOI: https://doi.org/10.5334/tohm.1007 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Feb 10, 2025
Accepted on: Apr 26, 2025
Published on: May 5, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Neurology,
telemedicine,
drug-induced movement disorder,
RE-AIM,
mental health

© 2025 Emily Houston, Amanda G. Kennedy, Terry Rabinowitz, Gail L. Rose, James Boyd, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 15 (2025): Issue 1Next article